0841 GMT - Uncertainty remains across the pharmaceutical industry until there is better visibility around the potential impact of U.S. tariffs, Shore Capital analyst Sean Conroy says in a note. U.S. President Trump announced across-the-board 10% tariffs on Wednesday on all imports and a 20% tariff on EU goods which, for now, exempts pharmaceuticals. GSK confirmed that there would be no changes to its outlook, whereas AstraZeneca said it will assess the implications of Trump's tariff announcement and Roche said it would consider additional U.S. investments. Shore Capital anticipates that stock prices might remain weak until companies can quantify the potential impact of tariffs on earnings and revenue, Conroy says. GSK's shares are up 1.5%, while AstraZeneca's are up 1.6% and Roche's are down 2.1%. (helena.smolak@wsj.com)
(END) Dow Jones Newswires
April 03, 2025 04:41 ET (08:41 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。